Opus Genetics, Inc. (NASDAQ: IRD) Stock Competitors & Peer Comparison

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, VRTX has a market cap of 133.7B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while VRTX trades at $526.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas VRTX's P/E ratio is 27.68. In terms of profitability, IRD's ROE is +11.48%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, IRD is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check VRTX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, MRNA has a market cap of 80.7B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while MRNA trades at $203.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas MRNA's P/E ratio is -24.96. In terms of profitability, IRD's ROE is +11.48%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, IRD is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for IRD.Check MRNA's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, REGN has a market cap of 77.3B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while REGN trades at $750.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas REGN's P/E ratio is 16.45. In terms of profitability, IRD's ROE is +11.48%, compared to REGN's ROE of +0.14%. Regarding short-term risk, IRD is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for IRD.Check REGN's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas VRNA's P/E ratio is -102.80. In terms of profitability, IRD's ROE is +11.48%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, IRD is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for IRD.Check VRNA's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, ARGX has a market cap of 60.4B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while ARGX trades at $970.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas ARGX's P/E ratio is 35.00. In terms of profitability, IRD's ROE is +11.48%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, IRD is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check ARGX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, RVMDW has a market cap of 44.4B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while RVMDW trades at $11.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas RVMDW's P/E ratio is -1.28. In terms of profitability, IRD's ROE is +11.48%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, IRD is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for IRD.Check RVMDW's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, RVMD has a market cap of 43.5B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while RVMD trades at $204.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas RVMD's P/E ratio is -23.18. In terms of profitability, IRD's ROE is +11.48%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, IRD is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for IRD.Check RVMD's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IRD's ROE is +11.48%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IRD is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for IRD.Check SGEN's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, ONC has a market cap of 39B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while ONC trades at $365.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas ONC's P/E ratio is 64.31. In terms of profitability, IRD's ROE is +11.48%, compared to ONC's ROE of +0.14%. Regarding short-term risk, IRD is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for IRD.Check ONC's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, ALNY has a market cap of 34B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while ALNY trades at $254.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas ALNY's P/E ratio is 45.78. In terms of profitability, IRD's ROE is +11.48%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, IRD is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for IRD.Check ALNY's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, ROIV has a market cap of 26.4B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while ROIV trades at $36.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas ROIV's P/E ratio is -34.72. In terms of profitability, IRD's ROE is +11.48%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, IRD is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for IRD.Check ROIV's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, INSM has a market cap of 25.1B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while INSM trades at $115.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas INSM's P/E ratio is -28.13. In terms of profitability, IRD's ROE is +11.48%, compared to INSM's ROE of -1.11%. Regarding short-term risk, IRD is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for IRD.Check INSM's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, INCY has a market cap of 25B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while INCY trades at $123.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas INCY's P/E ratio is 16.56. In terms of profitability, IRD's ROE is +11.48%, compared to INCY's ROE of +0.30%. Regarding short-term risk, IRD is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for IRD.Check INCY's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, BNTX has a market cap of 24.8B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while BNTX trades at $98.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas BNTX's P/E ratio is -12.78. In terms of profitability, IRD's ROE is +11.48%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, IRD is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check BNTX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, GMAB has a market cap of 21.8B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while GMAB trades at $35.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas GMAB's P/E ratio is 26.80. In terms of profitability, IRD's ROE is +11.48%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, IRD is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for IRD.Check GMAB's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, UTHR has a market cap of 20.4B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while UTHR trades at $481.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas UTHR's P/E ratio is 17.23. In terms of profitability, IRD's ROE is +11.48%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, IRD is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for IRD.Check UTHR's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IRD's ROE is +11.48%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, IRD is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for IRD.Check BGNE's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IRD's ROE is +11.48%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, IRD is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for IRD.Check DNA-WT's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while EXEL trades at $58.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas EXEL's P/E ratio is 16.76. In terms of profitability, IRD's ROE is +11.48%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, IRD is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for IRD.Check EXEL's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, JAZZ has a market cap of 14.6B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while JAZZ trades at $232.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas JAZZ's P/E ratio is 8.66. In terms of profitability, IRD's ROE is +11.48%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, IRD is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for IRD.Check JAZZ's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, ASND has a market cap of 14.2B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while ASND trades at $228.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas ASND's P/E ratio is -94.24. In terms of profitability, IRD's ROE is +11.48%, compared to ASND's ROE of +1.90%. Regarding short-term risk, IRD is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for IRD.Check ASND's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, NBIX has a market cap of 13.9B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while NBIX trades at $138.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas NBIX's P/E ratio is 19.99. In terms of profitability, IRD's ROE is +11.48%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, IRD is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check NBIX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, HALO has a market cap of 13.2B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while HALO trades at $111.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas HALO's P/E ratio is 20.81. In terms of profitability, IRD's ROE is +11.48%, compared to HALO's ROE of +1.81%. Regarding short-term risk, IRD is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for IRD.Check HALO's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, SMMT has a market cap of 13B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while SMMT trades at $16.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas SMMT's P/E ratio is -14.60. In terms of profitability, IRD's ROE is +11.48%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, IRD is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for IRD.Check SMMT's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, BBIO has a market cap of 12.9B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while BBIO trades at $65.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas BBIO's P/E ratio is -17.64. In terms of profitability, IRD's ROE is +11.48%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, IRD is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for IRD.Check BBIO's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IRD's ROE is +11.48%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IRD is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check KRTX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while MDGL trades at $509.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas MDGL's P/E ratio is -39.80. In terms of profitability, IRD's ROE is +11.48%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, IRD is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for IRD.Check MDGL's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, TWST has a market cap of 11.6B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while TWST trades at $186.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas TWST's P/E ratio is -83.84. In terms of profitability, IRD's ROE is +11.48%, compared to TWST's ROE of -0.30%. Regarding short-term risk, IRD is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for IRD.Check TWST's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while BMRN trades at $59.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas BMRN's P/E ratio is 28.78. In terms of profitability, IRD's ROE is +11.48%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, IRD is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for IRD.Check BMRN's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, TXG has a market cap of 11.4B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while TXG trades at $90.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas TXG's P/E ratio is -152.61. In terms of profitability, IRD's ROE is +11.48%, compared to TXG's ROE of -0.09%. Regarding short-term risk, IRD is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for IRD.Check TXG's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while TECH trades at $72.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas TECH's P/E ratio is 37.31. In terms of profitability, IRD's ROE is +11.48%, compared to TECH's ROE of +0.09%. Regarding short-term risk, IRD is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for IRD.Check TECH's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas RNAM's P/E ratio is -17.39. In terms of profitability, IRD's ROE is +11.48%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, IRD is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for IRD.Check RNAM's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while KRYS trades at $335.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas KRYS's P/E ratio is 41.99. In terms of profitability, IRD's ROE is +11.48%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, IRD is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for IRD.Check KRYS's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, AXSM has a market cap of 9.6B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while AXSM trades at $186.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas AXSM's P/E ratio is -48.60. In terms of profitability, IRD's ROE is +11.48%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, IRD is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for IRD.Check AXSM's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IRD's ROE is +11.48%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IRD is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check RXDX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, ARWR has a market cap of 9.3B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while ARWR trades at $66.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas ARWR's P/E ratio is -29.44. In terms of profitability, IRD's ROE is +11.48%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, IRD is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for IRD.Check ARWR's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, IBRX has a market cap of 9.2B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while IBRX trades at $8.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas IBRX's P/E ratio is -9.10. In terms of profitability, IRD's ROE is +11.48%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, IRD is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check IBRX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas NUVL's P/E ratio is -21.79. In terms of profitability, IRD's ROE is +11.48%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, IRD is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for IRD.Check NUVL's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while KYMR trades at $110.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas KYMR's P/E ratio is -34.53. In terms of profitability, IRD's ROE is +11.48%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, IRD is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for IRD.Check KYMR's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, PTGX has a market cap of 9.1B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while PTGX trades at $140.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas PTGX's P/E ratio is 136.86. In terms of profitability, IRD's ROE is +11.48%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, IRD is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check PTGX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas CRNX's P/E ratio is -16.86. In terms of profitability, IRD's ROE is +11.48%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, IRD is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check CRNX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, CAI has a market cap of 8.9B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while CAI trades at $31.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas CAI's P/E ratio is 88.65. In terms of profitability, IRD's ROE is +11.48%, compared to CAI's ROE of +0.19%. Regarding short-term risk, IRD is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for IRD.Check CAI's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IRD's ROE is +11.48%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, IRD is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for IRD.Check IMGN's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while TGTX trades at $56.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas TGTX's P/E ratio is 20.36. In terms of profitability, IRD's ROE is +11.48%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, IRD is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check TGTX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IRD's ROE is +11.48%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, IRD is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for IRD.Check BPMC's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas APGE's P/E ratio is -31.19. In terms of profitability, IRD's ROE is +11.48%, compared to APGE's ROE of -0.30%. Regarding short-term risk, IRD is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for IRD.Check APGE's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas CERE's P/E ratio is -16.47. In terms of profitability, IRD's ROE is +11.48%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IRD is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for IRD.Check CERE's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while PCVX trades at $56.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas PCVX's P/E ratio is -7.43. In terms of profitability, IRD's ROE is +11.48%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, IRD is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check PCVX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while CYTK trades at $65.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas CYTK's P/E ratio is -9.09. In terms of profitability, IRD's ROE is +11.48%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, IRD is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for IRD.Check CYTK's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, PRAX has a market cap of 7.9B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while PRAX trades at $281.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas PRAX's P/E ratio is -21.78. In terms of profitability, IRD's ROE is +11.48%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, IRD is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check PRAX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, IONS has a market cap of 7.6B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while IONS trades at $45.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas IONS's P/E ratio is -14.03. In terms of profitability, IRD's ROE is +11.48%, compared to IONS's ROE of -1.11%. Regarding short-term risk, IRD is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for IRD.Check IONS's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas MTSR's P/E ratio is -23.58. In terms of profitability, IRD's ROE is +11.48%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, IRD is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for IRD.Check MTSR's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, SYRE has a market cap of 7.4B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while SYRE trades at $84.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas SYRE's P/E ratio is -43.45. In terms of profitability, IRD's ROE is +11.48%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, IRD is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for IRD.Check SYRE's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, ABVX has a market cap of 7.2B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while ABVX trades at $98.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas ABVX's P/E ratio is -18.75. In terms of profitability, IRD's ROE is +11.48%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, IRD is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check ABVX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while IMVT trades at $33.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas IMVT's P/E ratio is -11.87. In terms of profitability, IRD's ROE is +11.48%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, IRD is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for IRD.Check IMVT's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas MRUS's P/E ratio is -17.05. In terms of profitability, IRD's ROE is +11.48%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, IRD is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for IRD.Check MRUS's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas ACLX's P/E ratio is -28.27. In terms of profitability, IRD's ROE is +11.48%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, IRD is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check ACLX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, BLTE has a market cap of 6.7B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while BLTE trades at $166.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas BLTE's P/E ratio is -89.12. In terms of profitability, IRD's ROE is +11.48%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, IRD is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for IRD.Check BLTE's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas RETA's P/E ratio is -66.29. In terms of profitability, IRD's ROE is +11.48%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IRD is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for IRD.Check RETA's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, RYTM has a market cap of 6.6B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while RYTM trades at $95.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas RYTM's P/E ratio is -30.77. In terms of profitability, IRD's ROE is +11.48%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, IRD is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for IRD.Check RYTM's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, IOVA has a market cap of 6.5B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while IOVA trades at $14.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas IOVA's P/E ratio is -19.79. In terms of profitability, IRD's ROE is +11.48%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, IRD is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for IRD.Check IOVA's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas CNTA's P/E ratio is -22.63. In terms of profitability, IRD's ROE is +11.48%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, IRD is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for IRD.Check CNTA's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, CGON has a market cap of 6.2B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while CGON trades at $70.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas CGON's P/E ratio is -26.22. In terms of profitability, IRD's ROE is +11.48%, compared to CGON's ROE of -0.25%. Regarding short-term risk, IRD is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for IRD.Check CGON's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, LGND has a market cap of 6.2B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while LGND trades at $310.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas LGND's P/E ratio is 34.07. In terms of profitability, IRD's ROE is +11.48%, compared to LGND's ROE of +0.20%. Regarding short-term risk, IRD is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for IRD.Check LGND's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while SRRK trades at $47.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas SRRK's P/E ratio is -13.85. In terms of profitability, IRD's ROE is +11.48%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, IRD is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for IRD.Check SRRK's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, KOD has a market cap of 5.7B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while KOD trades at $91.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas KOD's P/E ratio is -21.85. In terms of profitability, IRD's ROE is +11.48%, compared to KOD's ROE of -2.73%. Regarding short-term risk, IRD is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for IRD.Check KOD's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas CDTX's P/E ratio is -19.77. In terms of profitability, IRD's ROE is +11.48%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, IRD is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check CDTX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, TVTX has a market cap of 5.6B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while TVTX trades at $59.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas TVTX's P/E ratio is -133.31. In terms of profitability, IRD's ROE is +11.48%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, IRD is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check TVTX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IRD's ROE is +11.48%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IRD is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for IRD.Check ABCM's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IRD's ROE is +11.48%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IRD is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for IRD.Check ISEE's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while PTCT trades at $64.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas PTCT's P/E ratio is -27.88. In terms of profitability, IRD's ROE is +11.48%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, IRD is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for IRD.Check PTCT's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while COGT trades at $31.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas COGT's P/E ratio is -15.00. In terms of profitability, IRD's ROE is +11.48%, compared to COGT's ROE of -0.73%. Regarding short-term risk, IRD is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for IRD.Check COGT's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while CRSP trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas CRSP's P/E ratio is -11.76. In terms of profitability, IRD's ROE is +11.48%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, IRD is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for IRD.Check CRSP's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, MIRM has a market cap of 5.3B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while MIRM trades at $87.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas MIRM's P/E ratio is -6.02. In terms of profitability, IRD's ROE is +11.48%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, IRD is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for IRD.Check MIRM's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas APLS's P/E ratio is 38.35. In terms of profitability, IRD's ROE is +11.48%, compared to APLS's ROE of +0.40%. Regarding short-term risk, IRD is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for IRD.Check APLS's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, DFTX has a market cap of 5.1B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while DFTX trades at $38.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas DFTX's P/E ratio is N/A. In terms of profitability, IRD's ROE is +11.48%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, IRD is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check DFTX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, ORKA has a market cap of 5B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while ORKA trades at $82.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas ORKA's P/E ratio is -42.31. In terms of profitability, IRD's ROE is +11.48%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, IRD is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for IRD.Check ORKA's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, ERAS has a market cap of 4.9B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while ERAS trades at $14.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas ERAS's P/E ratio is -15.28. In terms of profitability, IRD's ROE is +11.48%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, IRD is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for IRD.Check ERAS's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, MANE has a market cap of 4.9B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while MANE trades at $117.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas MANE's P/E ratio is -37.51. In terms of profitability, IRD's ROE is +11.48%, compared to MANE's ROE of -0.38%. Regarding short-term risk, IRD is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for IRD.Check MANE's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, DNTH has a market cap of 4.9B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while DNTH trades at $87.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas DNTH's P/E ratio is -21.00. In terms of profitability, IRD's ROE is +11.48%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, IRD is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for IRD.Check DNTH's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas TERN's P/E ratio is -51.41. In terms of profitability, IRD's ROE is +11.48%, compared to TERN's ROE of -0.20%. Regarding short-term risk, IRD is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for IRD.Check TERN's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, ADPT has a market cap of 4.6B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while ADPT trades at $28.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas ADPT's P/E ratio is -70.17. In terms of profitability, IRD's ROE is +11.48%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, IRD is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for IRD.Check ADPT's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas FOLD's P/E ratio is -161.00. In terms of profitability, IRD's ROE is +11.48%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, IRD is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for IRD.Check FOLD's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, ABCL has a market cap of 4.5B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while ABCL trades at $14.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas ABCL's P/E ratio is -27.44. In terms of profitability, IRD's ROE is +11.48%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, IRD is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for IRD.Check ABCL's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas AKRO's P/E ratio is -14.57. In terms of profitability, IRD's ROE is +11.48%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, IRD is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for IRD.Check AKRO's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IRD's ROE is +11.48%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IRD is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for IRD.Check ALPN's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas OPT's P/E ratio is -1.52. In terms of profitability, IRD's ROE is +11.48%, compared to OPT's ROE of +1.18%. Regarding short-term risk, IRD is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for IRD.Check OPT's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas PRTC's P/E ratio is -3.78. In terms of profitability, IRD's ROE is +11.48%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, IRD is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for IRD.Check PRTC's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, EWTX has a market cap of 4.2B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while EWTX trades at $39.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas EWTX's P/E ratio is -21.18. In terms of profitability, IRD's ROE is +11.48%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, IRD is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check EWTX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IRD's ROE is +11.48%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IRD is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check MRTX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while RLAY trades at $18.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas RLAY's P/E ratio is -11.69. In terms of profitability, IRD's ROE is +11.48%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, IRD is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for IRD.Check RLAY's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, TNGX has a market cap of 4B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while TNGX trades at $24.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas TNGX's P/E ratio is -29.42. In terms of profitability, IRD's ROE is +11.48%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, IRD is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check TNGX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas CPRX's P/E ratio is 17.49. In terms of profitability, IRD's ROE is +11.48%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, IRD is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check CPRX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while TLX trades at $11.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas TLX's P/E ratio is 118.37. In terms of profitability, IRD's ROE is +11.48%, compared to TLX's ROE of +0.07%. Regarding short-term risk, IRD is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check TLX's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, CELC has a market cap of 3.8B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while CELC trades at $77.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas CELC's P/E ratio is -18.00. In terms of profitability, IRD's ROE is +11.48%, compared to CELC's ROE of -3.51%. Regarding short-term risk, IRD is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for IRD.Check CELC's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IRD's ROE is +11.48%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IRD is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for IRD.Check RYZB's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IRD's ROE is +11.48%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IRD is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for IRD.Check CBAY's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, PBLS has a market cap of 3.7B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while PBLS trades at $31.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas PBLS's P/E ratio is -16.97. In terms of profitability, IRD's ROE is +11.48%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, IRD is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for IRD.Check PBLS's competition here

Opus Genetics, Inc. (NASDAQ: IRD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IRD stands at 409.1M. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, IRD is priced at $4.96 on the NASDAQ, while VKTX trades at $31.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IRD currently has a P/E ratio of -3.87, whereas VKTX's P/E ratio is -6.83. In terms of profitability, IRD's ROE is +11.48%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, IRD is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for IRD.Check VKTX's competition here